Susceptibility of Candida albicans to common and novel antifungal drugs, and relationship between the mating type locus and resistance, in Lebanese hospital isolates

Mycoses

Volumn 52, Issue 2, 2009, Pages 141-148

  Basma, Raida ^a   Barada, Ghyda ^a   Ojaimi, Naim ^a   Khalaf, Roy A ^a  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

Azoles; Candida albicans; Caspofungin; Cross resistance; Homozygosity; MTL locus

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ALLELE; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CLINICAL ASSESSMENT; CLINICAL FEATURE; EPSILOMETER TEST; FUNGAL GENE; FUNGAL STRAIN; FUNGUS ISOLATION; GENE LOCUS; HOMOZYGOSITY; HOSPITAL; HUMAN; INCIDENCE; LEBANON; MATING TYPE; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GENES, MATING TYPE, FUNGAL; HOMOZYGOTE; HOSPITALS; HUMANS; LEBANON; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION;

CANDIDA ALBICANS;

EID: 59149100239     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2008.01559.x     Document Type: Article

References (53)

1. Cowen LE, Anderson JB, Kohn LM. Evolution of drug resistance in Candida albicans. Annu Rev Microbiol 2002 56 : 139 65.
2. Odds FC, Gow NA, Brown AJ. Fungal virulence studies come of age. Genome Biol 2001 3 : 1009.1 4.
3. Xu J, Ramos AR, Vilgalys R, Mitchell TG. Clonal and spontaneous origins of fluconazole resistance in Candida albicans. J Clin Microbiol 2000 38 : 1214 20.
4. Molero G, Diez-Orejaz R, Navarro-Garcia F et al. Candida albicans: genetics, dimorphism and pathogenicity. Int Microbiol 1998 1 : 95 106.
5. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial bloodstream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998 31 : 32732.
6. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000 30 : 653 7.
7. Georgopapadakou NH, Walsh TJ. Human mycoses: drugs and targets for emerging pathogens. Science 1994 264 : 371 3.
8. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999 12 : 40 79.
9. Georgopapadakou NH. Antifungals: mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol 1998 1 : 547 57.
10. Tkacz JS, DiDomenico B. Antifungals: what's in the pipeline. Curr Opin Microbiol 2001 4 : 540 5.
11. DiDomenico B. Novel antifungal drugs. Curr Opin Microbiol 1999 2 : 509 15.
12. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998 11 : 382 402.
13. Law D, Moore BC, Wardle MH, Ganguli AL, Keaney GM, Denning WD. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994 34 : 659 86.
14. Lyons CN, White TC. Transcriptional analysis of antifungal drug resistance in Candida albicans. Antimicrob Agents Chemother 2000 44 : 2296 303.
15. Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on beta-1, 3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001 10 : 269 80.
16. Hellstein J, Vawter-Hugart H, Fotos P, Schmid J, Soll DR. Genetic similarity and phenotypic diversity of commensal and pathogenic strains of Candida albicans isolated from the oral cavity. J Clin Microbiol 1993 31 : 3190 9.
17. Gupta AK, Tomas E. New antifungal agents. Dermatol Clin 2003 21 : 565 76.
18. Schafer-Korting M. New systemic antifungal drugs: mechanisms of action, drug interactions and side effects. Mycoses 2003 1 : 28 31.
19. Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity followed prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006 57 : 705 8.
20. Soll DR, Lockhart SR, Zhao R. Relationship between switching and mating in Candida albicans. Eukaryot Cell 2003 2 : 390 7.
21. Lockhart SR, Pujol C, Daniels K, Miller M, Johnson A, Soll DR. In Candida albicans, white opaque switchers are homozygous for mating type. Genetics 2002 162 : 737 45.
22. Tsong AE, Miller MG, Raisner RM, Johnson AD. Evolution of a combinatorial transcriptional circuit: a case study in yeasts. Cell 2003 115 : 389 99.
23. Wu W, Pujol C, Lockhart SR, Soll DR. Chromosome loss followed by duplication is the major mechanism of spontaneous mating type locus homozygosis in Candida albicans. Genetics 2005 169 : 1311 27.
24. Hull CM, Raisner RM, Johnson AD. Evidence for mating of the "asexual" yeast Candida albicans in a mammalian host. Science 2000 289 : 307 10.
25. Lockhart SR, Daniels KJ, Zhao R, Wessels D, Soll DR. Cell biology of mating in Candida albicans. Eukaryot Cell 2003 2 : 49 61.
26. Magee BB, Magee PT. Induction of mating in Candida albicans by construction of MTLa and MTLα strains. Science 2000 289 : 310 3.
27. Soll DR. High frequency switching in Candida albicans. Clin Microbiol Rev 1992 5 : 183 203.
28. Kvaal C, Lachke SA, Srikantha T, Daniels K, McCoy J, Soll DR. Misexpression of the opaque phase-specific gene PEP1 (SAP1) in the white phase of Candida albicans confers increased virulence in a mouse model of cutaneous infection. Infect Immun 1999 67 : 6652 62.
29. Lan C, Newport G, Murillo LA et al. Metabolic specialization associated with phenotypic switching in Candida albicans. PNAS 2002 99 : 14907 12.
30. Rustad TR, Stevens DA, Pfaller MA, White TC. Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiol 2002 148 : 1061 72.
31. Pujol C, Messer SA, Pfaller M, Soll DR. Drug resistance is not directly affected by mating type locus zygosity in Candida albicans. Antimicrob Agents Chemother 2003 47 : 1207 12.
32. Maxwell MJ, Messer SA, Hollis RJ et al. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol 2003 41 : 1087 90.
33. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts: Approved Standard, M27-A. Wayne, PA : NCCLS, 1997.
34. Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol 2003 41 : 1875 80.
35. Pfaller MA, Diekema DJ, Messer SA et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003 41 : 78 83.
36. Pfaller MA, Messer SA, Houston A, Mills K, Bolmstrom A, Jones RN. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J Clin Microbiol 2000 38 : 315 3717.
37. Pfaller MA, Messer SA, Mills K, Bolmstrom A, Jones RN. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol 2001 39 : 4387 9.
38. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro/in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997 24 : 235 47.
39. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekemam DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002 46 : 1723 7.
40. Park BJ, Arthington-Skaggs BA, Hajjeh RA et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 2006 50 : 1287 92.
41. Peyron F, Favel A, Michel-Nguyen A, Gilly M, Regli P, Blomstrom A. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J Clin Microbiol 2001 39 : 339 42.
42. Pina-Vaz C, Costa-de-Oliveira S, Rodrigues AG, Espinel-Ingroff A. Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry. J Clin Microbiol 2005 43 : 4674 9.
43. Yazbek S, Barada G, Basma R, Mahfouz J, Khalaf RA. Significant discrepancy between real time PCR identification and hospital identification of C. albicans from Lebanese patients. Med Sci Monit 2007 13 : MT7 MT12.
44. Espinel-Ingroff A, Pfaller MA, Erwin ME, Jones RN. Interlaboratory evolution of E-test method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol 1996 34 : 848 52.
45. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002 40 : 852 6.
46. Pfaller MA, Messer SA, Boyken L et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Microbiol Infect Dis 2004 48 : 3137 41.
47. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiol 1997 143 : 405 16.
48. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995 39 : 2378 86.
49. Sanguinetti M, Posteraró B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005 49 : 668 79.
50. Perea S, Lopez-Ribot JL, Kirkpatrick WR et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001 45 : 2676 84.
51. Hernandez S, López-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004 48 : 1382 3.
52. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004 48 : 3407 11.
53. Coste A, Turner V, Ischer F et al. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal drug resistance in Candida albicans. Genetics 2006 172 : 2139 56.